Last reviewed · How we verify
mFOLFOX7
At a glance
| Generic name | mFOLFOX7 |
|---|---|
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Diarrhoea
- Dermatitis acneiform
- Rash
- Vision blurred
- Abdominal pain
- Vomiting
- Oedema peripheral
- Pyrexia
- Blood alkaline phosphatase increased
- Blood creatine phosphokinase increased
- Blood lactate dehydrogenase increased
Key clinical trials
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (PHASE1)
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (PHASE2)
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC (PHASE3)
- Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (PHASE3)
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (PHASE1)
- BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (PHASE1, PHASE2)
- Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (PHASE1)
- mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mFOLFOX7 CI brief — competitive landscape report
- mFOLFOX7 updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI